TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Shared Decision Making and How It Impacts the Patient Understanding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* - Aged 45 to 64 years~* Mild to moderate knee pain consistent with a diagnosis of osteoarthritis by the clinician~* Self-identified as African American and/or Hispanic~* At least one of the following comorbidities:~  1. Obesity (BMI ≥ 30),~ 2. Hypertension (ICD10 codes below)~ 3. Diabetes (ICD10 codes below)~Exclusion Criteria:~* - Known inflammatory arthritis (Lupus, Sjogrens, rheumatoid arthritis)~* Prior total knee replacement~* Recommended total knee replacement~* Acute knee trauma

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Standard patient information data sheet (Type: NO_INTERVENTION): None
- SDM Tool (Type: EXPERIMENTAL): A simple, one-page tool that provides a framework for the patient discussion, which improves the consistency of the patient-provider communication. This SDM can also be customized to a specific patient based on gender, race/ethnicity, age, and select comorbidities (obesity, hypertension and diabetes).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with a history of breast cancer surgery either lumpectomy, mastectomy, axillary node dissection or sentinel node biopsy at least one year ago and received either radiation therapy or chemotherapy or both~* Patients with no active disease; (as defined as no detectable disease)~* Patients with stable metastatic disease which is defined as (metastatic tumor demonstrates no increase in volume, tumor size or diameter and no evidence of new lesions, have been identified during last assessment by medical oncologist/radiologist or surgeons)~* Signed informed consent~Exclusion Criteria:~* Survivors of breast cancer that have not received either breast surgery or radiation therapy~* Patients with known cognitive impairments~* Individuals with progressive metastatic disease in which the tumor has increased in size, volume and diameter or evidence of new lesions, as noted by medical oncologists, radiologists and surgeons~* individuals who are non-ambulatory~* Women who self-report to be pregnant~  * As this is an observational study, we will not be performing a pregnancy test, participants will be asked if they are or are not pregnant

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supportive care (musculoskeletal screening, quality of life) (Type: EXPERIMENTAL): Patients complete the DASH and FACT-B questionnaires over 30-45 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Early Versus Late Amniotomy Following EAB Cervical Ripening

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Gestational age 37-42 weeks~2. Singleton pregnancy~3. Vertex presentation~4. Medical indication for induction of labor~5. Need for cervical ripening (Bishop score \<=6)~6. Consent to participate in the study~7. Women age at or \>18 years~Exclusion Criteria:~1. Multiple pregnancies~2. Preterm pregnancy~3. Previous cesarean section~4. Uterine malformation~5. Withdrawal of consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Early amniotomy group (Type: OTHER): Amniotomy will be performed as the exclusive primary intervention. Oxytocin infusion will begin as per local standard dose protocol no earlier than 2 hours following amniotomy.
- Late amniotomy group (Type: OTHER): Oxytocin infusion will begin as per local standard dose protocol. Amniotomy will be performed no earlier than 2 hours following the commence of oxytocin infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bloodtranfusions After Aortic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective surgery for thoracic aneurysm~Exclusion Criteria:~* Prior trombosis or myocardial infarction, congenital coagulation disorder, use of anti-coagulants prior to surgery, prior thoracic surgery, pregnancy, pre-operative fibrinogen concentration \<1g/L

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Haemocomplettan P (Type: EXPERIMENTAL): Study patients that receive Haemocomplettan P
- NaCl 0.9% (Type: PLACEBO_COMPARATOR): Study patients that receive NaCl 0.9%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CoNCReTe-trial: Colles Fractures, Determining the Norm in Closed Reduction Techniques

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients of 16 years and older visiting our EMD with newly diagnosed closed distal radius fractures:~* within 2cm of the radiocarpal joint~* with dorsoradial dislocation (Colles' fractures),~* AO-type 23.A2 and 23.A3 (extra-articular) and 23-C1 and 23-C2 (intra-articular)~* which are in need for reduction. I.e. Colles' fractures:~  * with loss of ≥2mm of radial height (RH),~ * change of ≥5º of radial inclination (RI),~ * loss of ≥10º volar tilt (VT),~ * loss of reduction of the distal radioulnar (DRU) joint and/or~ * fractures with \>1mm intra-articular step-off~Exclusion Criteria:~* Patients who will not have their follow-up in our hospital~* Patients \<16 year old~* Greenstick fractures~* Additional fractures of carpalia or elbow joint~* Patients suffering a High Energy Trauma (HET)~* Fractures that do not need reduction (see 4.2 for definition)~* Patients with pre-existent wrist-trauma or pathological bone except for osteoporosis (cyst, metastasis)~* Patients who cannot give informed consent or do not understand the Dutch language~* Patients with bilateral fractures~* Open fractures~* Fractures \>48h old~* (Smith, Barton, reversed Barton or Chauffeurs fractures)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Manual Manipulation
- 2 (Type: ACTIVE_COMPARATOR): Finger Trap Traction

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients demonstrate normal serum creatinine and no radiological evidence of a renal tumor.~OR~* Patients diagnosed with renal cancer and normal creatinine.~Exclusion Criteria:~* None.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): Patients demonstrate normal serum creatinine and no radiological evidence of a renal tumor.
- p 2 (Type: None): Patients diagnosed with renal cancer and normal creatinine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Letrozole in Patients With Hepatopulmonary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Diagnosis of moderate to very severe hepatopulmonary syndrome which consists of having all 3 of the following conditions:~  * Presence of liver disease or portal hypertension~ * Intrapulmonary shunting on contrast-enhanced echocardiogram~ * Hypoxemia \[A-a gradient ≥15mmHg (or ≥20mmHg if age \>64) and PaO2\<80mmHg on arterial blood gas testing\]~* Child-Pugh class A or B liver disease~* MELD score \< 20~* ≥ 18 years old~* Female subjects must be post-menopausal (defined as 12 months of spontaneous amenorrhea or 6 weeks postsurgical bilateral oophorectomy without or without hysterectomy)~* Ability to provide informed consent~Exclusion Criteria~* Enrollment in a clinical trial or concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 28 days of baseline~* Current hepatic encephalopathy~* Expectation of liver transplant within six months of randomization~* Concomitant lung disease defined as restriction (TLC \< 70%) or obstruction (FEV1 \< 80% \& FEV1/FVC \< 70%)~* Inability to comply with the study protocol~* Osteoporosis~* Premenopausal women (those who have not reached 1 year absence of menarche)~* Vulnerable study population, including imprisoned individuals, or those who cannot consent on their own.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Letrozole Group (Type: EXPERIMENTAL): Subjects with hepatopulmonary syndrome will get the study drug letrozole
- Placebo Group (Type: PLACEBO_COMPARATOR): Subjects with hepatopulmonary syndrome will get the study placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hypofractionated Radiotherapy for Nonmelanoma Skin Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cosmesis not important~* Basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) of any differentiation~* Clinical stage I and II~* Location on the thorax, abdomen, pelvis (except perineum), arm, thigh, cheek~* Patient with up to 3 injuries eligible for the study~* Karnofsky Performance Status (KPS) ≥ 70%~* Age \> 18 years~* Informed Consent signed by the patient consenting to undergo the study~Exclusion Criteria:~* Indian Race~* Prior treatment for their skin cancer~* More than three synchronous lesions to treatment with RT~* Basal syndrome, xeroderma, vitiligo and albinism~* Immunosuppression~* Prior burn at the tumor site~* Tumor \> 5 cm~* Age \<18 years~* Carrier mental incapacity~* People in a relationship of dependence as prisoners, soldiers, students, staff, etc..

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 30 Gy in 5 fractions of 6 Gy (Type: EXPERIMENTAL): tumors ≤ 2 cm in diameter: 5 fractions of 600 cGy, once a day, five times a week - TDF: 89
- 40 Gy in 10 fractions of 4 Gy (Type: EXPERIMENTAL): tumors \> 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Examining Exercise, Health Coaching and Meditation for University Employees

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Employees at York University;~* fluency in English;~* provision of informed consent~Exclusion Criteria:~* currently engaged in regular exercise programs or routines which meet or exceed the Canadian Physical Activity Guidelines~* neurological or musculoskeletal co-morbidities inhibiting participation in exercise program~* \> 65 years old;~* medical history of cardiovascular diseases such as CAD and CHF, uncontrolled hypertension~* currently engaged in a mindfulness meditation program or meditative practice at advanced levels;~* not in possession of a smartphone (android/i-phone)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Exercise and Health Coaching (Type: ACTIVE_COMPARATOR): Walking exercise protocol program, carried out by themselves, over 12 weeks.~Health Coach addresses various topics with participant, half-hour sessions on a weekly (12 sessions)
- Exercise, Health Coaching and Meditation (Type: EXPERIMENTAL): Walking exercise protocol program, carried out by themselves, over 12 weeks.~Health Coach addresses various topics with participant, half-hour sessions on a weekly (12 sessions)~Mindfulness Meditation intervention will incorporate varied types of MBI techniques 3 times per week for 12 weeks, during work hours and/or during their time on campus (after work hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female with persistent atrial fibrillation, aged 21 or older~* Duration of atrial fibrillation less than one year~* The patient does not have any contraindications for anticoagulation~* The patient is willing to participate in the study for a total of 6 months with 3 outpatient office visits~* The patient has provided written informed consent during the screening visit to any test or procedure being performed, or medication being changed, for this study.~* The patient has no clinically significant abnormal clinical laboratory values, which in the investigator's opinion precludes the patient from safely participating in the study.~Exclusion Criteria:~* Any contraindication for anticoagulation~* New York Heart Association class IV heart failure~* Currently taking anti-arrhythmic drugs~* Chronic kidney disease (serum creatinine less than 2.5mg/dL) or severe liver dysfunction~* Pregnancy/nursing~* Prolonged QT interval (\>500ms)~* Taking other medications known to prolong the QT interval~* Taking other medications known to affect the metabolism of ranolazine

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranolazine (Type: EXPERIMENTAL): Patients will be started on ranolazine 500mg twice daily. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated.
- Placebo (Type: PLACEBO_COMPARATOR): Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Chronic Supplementation of L-arginine in the Muscular Performance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Healthy young adults for both sex; Age between 20 and 55 years; Slight or moderate physical activity, 30 minutes per day, at least 3 times a week;~Exclusion criteria:~Cardiac or pulmonary disease; Previous history of knee surgery or skeletal muscular dysfunctions in hip, knee or ankle joints; Athletic person (intensive anaerobic activity); None practiced of physical activity regularly; Medications usage~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): L-arginine aspartate (Targifor)
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Electrophysiology of the Human Pituitary Gland

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients undergoing transsphenoidal surgery for pituitary adenoma.~* Identification of the posterior lobe on preoperative MRI. This is most common in patients with micro-adenomas or small macroadenomas.~* Age \>18 years~Exclusion Criteria:~* Emergency surgery~* Cognitive impairments~* Pregnancy~* Pre-existing diabetes insipidus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention arm (Type: EXPERIMENTAL): Patients undergoing the extra intra-operative electrophysiological measurement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Insulin Resistance in Non-alcoholic Fatty Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Control subjects: nl liver enzymes and no history of liver disease Case subjects: NAFLD on liver biopsy within the past 3 years or presumed NAFLD with otherwise unexplained elevated alanine aminotransferase (ALT) and fatty liver by computerized tomography (CT) scan or ultrasound~* Able to comply with taking 1 pill a day for 6 months and follow-up safety visits~Exclusion Criteria:~* Cases: cirrhosis on liver biopsy or by clinical exam or fibrosis score~* Causes of liver dysfunction other than NASH~* Use of medications associated with hepatic steatosis:~  * glucocorticoids~ * estrogens~ * tamoxifen~ * amiodarone~ * accutane~ * sertraline~* Use of medications that cause insulin resistance:~  * niacin~ * glucocorticoids~ * anti-HIV drugs or atypical antipsychotics~* Use of lipid-lowering medications except stable dose statin~* Use of anti-NASH drugs such as ursodeoxycholic acid, betaine milk thistle~* Use of coumadin~* Use of nitrates~* Significant alcohol consumption: Average \>20 grams/day~* In subjects with diabetes, a hemoglobin A1c (HbA1c) \>7.5% or use of insulin, metformin, rosiglitazone or pioglitazone~* Liver transaminases: ALT \>5x upper limit of normal,~* Iron saturation \>50%~* Creatinine \>1.5 mg/dl for men and \>1.4 mg/dl for women~* Hematocrit \<33%~* Pregnancy or lactation~* Significant weight loss within the past 6 months or since the liver biopsy~* History of significant coronary artery disease or congestive heart failure, retinopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): matching placebo 1 po qd
- Fenofibrate (Type: EXPERIMENTAL): micronized fenofibrate 200 mg 1 po qd
- Pioglitazone (Type: EXPERIMENTAL): pioglitazone 30 mg po qd

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Management of Uncontrolled Hypertension (HTN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Age ≥ 18 years~2. Blood pressure of \>130/80 mmHg~3. Currently receiving 3 anti-hypertensive agents, one of which is a diuretic, for at least six weeks~Exclusion criteria~1. Vulnerable populations~1. Pregnant women~2. Prisoners~3. Cognitively impaired persons~4. Economically and/or educationally disadvantaged~5. Human fetuses and neonates~6. Patients who work night-shift~7. Children~8. Conditions with visual field deterioration (Anterior Ischemic Optic Neuropathy, Glaucoma, Optic Nerve Disorders)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Chronotherapy (Type: ACTIVE_COMPARATOR): Chronotherapy group automatically receives a shift in 1 anti-hypertensive medication to night-time without assessment of ambulatory blood pressure monitor results.
- ABPM (Type: ACTIVE_COMPARATOR): ABPM group will have their ambulatory blood pressure monitor results reviewed prior to deciding to change regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues